期刊
BIOLOGICAL & PHARMACEUTICAL BULLETIN
卷 40, 期 11, 页码 1968-1975出版社
PHARMACEUTICAL SOC JAPAN
DOI: 10.1248/bpb.b17-00548
关键词
anaplastic lymphoma kinase; nuclear tyrosine kinase; A-kinase anchoring protein 8; heterochromatinization; alternative transcription initiation; chromatin structural change
资金
- Ministry of Education, Culture, Sports, Science and Technology of Japan
- Hamaguchi Foundation for the Advancement of Biochemistry
- Japan Foundation for Applied Enzymology
- Promotion and Mutual Aid Corporation for Private Schools of Japan (Kyoto Pharmaceutical University)
- Promotion and Mutual Aid Corporation for Private Schools of Japan (Chiba University)
- [16K08227]
- [15K07922]
- Grants-in-Aid for Scientific Research [17K15985, 15K07922, 16J04141, 16K08227] Funding Source: KAKEN
Anaplastic lymphoma kinase (ALK) is a receptor-type tyrosine kinase that promotes cell growth upon stimulation with ligands such as midkine and pleiotrophin. Recently, a truncated isoform of ALK was identified in a variety of tumors. This isoform is expressed from a novel ALK transcript initiated from a de novo alternative transcription initiation (ATI) site in ALK intron 19 (referred to as ALK(ATI)). ALK(ATI), which consists of only the intracellular kinase domain, localizes to the nucleus as well as the cytoplasm. However, its nuclear role is unknown. In this study, we determined that ALK(ATI) promoted chromatin structural changes in the nucleus in a kinase activity-dependent manner. We found that expression of ALK(ATI) increased the level of the heterochromatin marker Lys9 tri-methylated histone 113. In addition, we demonstrated that ALK(ATI) phosphorylated the nuclear protein A-kinase anchoring protein 8 (AKAP8) and altered its subcellular localization from the insoluble fraction to the soluble fraction. These results suggest that ALK(ATI) induces chromatin structural changes and heterochromatinization through phosphorylation of AKAP8 in the nucleus.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据